Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,497 across all filing types
Latest filing 2022-04-12 Management Reports
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
独立董事述职报告 （雷新途）
Management Reports Classification · 95% confidence The document is titled as the "2021年度独立董事述职报告" which translates to "2021 Annual Independent Director's Work Report". It details the independent director's activities, opinions on various board meetings, audit committee meetings, and other governance-related matters throughout the year 2021. The content includes detailed independent opinions on company matters such as stock incentive plans, use of raised funds, audit firm reappointment, internal control evaluation, and other governance and supervisory activities. It is a comprehensive report on the independent director's duties and oversight for the year 2021. This type of document is a management report focusing on governance, oversight, and detailed explanations of company operations and decisions from the perspective of the independent director. It is not an annual report (10-K), audit report, or a simple announcement. It is not a transcript, capital update, or voting result. It fits best under Management Reports (MDA) as it provides detailed explanations of financial results, business trends, and outlook from management's perspective, specifically the independent director's report on their duties and opinions.
2022-04-12 Chinese
独立董事候选人声明（刘洪泉）
Regulatory Filings Classification · 95% confidence The document is a formal declaration by an independent director candidate of a company, confirming compliance with various legal and regulatory requirements for serving as an independent director. It contains no financial data, no report or presentation, and no announcement of voting results or management changes. It is a regulatory compliance statement related to board membership qualifications. The document length is short (3130 characters), and it is not an announcement of a report publication but a standalone declaration. This type of document fits best under Regulatory Filings (RNS) as it is a compliance filing that does not fit other specific categories.
2022-04-12 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 23rd meeting of the 7th Board of Directors of 亿帆医药股份有限公司, held on April 11, 2022. It includes voting results on various reports and proposals such as the 2021 annual general manager work report, 2021 annual board work report, 2021 financial statements, 2021 annual report and its summary, profit distribution plan, audit firm appointment, internal audit and control reports, and other governance and operational matters. It also includes the nomination of candidates for the 8th Board of Directors and amendments to company bylaws and governance rules. The document references the 2021 annual report and other reports that will be submitted to the 2021 annual shareholders meeting for approval, but this document itself is not the annual report. Instead, it is a formal announcement of board meeting resolutions, including management and governance decisions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management. The document length (9870 characters) and content confirm it is not a brief announcement or a report publication announcement but a substantive board meeting resolution announcement.
2022-04-12 Chinese
证券投资与衍生品交易管理制度
Governance Information Classification · 95% confidence The document is titled "证券投资与衍生品交易管理制度" which translates to "Securities Investment and Derivatives Trading Management System." It is a detailed internal policy document outlining the principles, decision-making authority, management, reporting procedures, and disclosure requirements related to securities investment and derivatives trading by the company and its subsidiaries. The document includes governance rules, risk control measures, internal audit responsibilities, and compliance with regulatory disclosure obligations. It is not a financial report, earnings release, or announcement but rather an internal governance and management system document. This fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is about 4966 characters, and it is substantive, not a brief announcement or certification. Therefore, the classification is CGR with high confidence.
2022-04-12 Chinese
投资者关系管理制度(2022年4月修订)
Governance Information Classification · 95% confidence The document is titled '投资管理制度' (Investment Management System) and '投资者关系管理制度' (Investor Relations Management System) for Yifan Pharmaceutical Co., Ltd. It details the company's policies and procedures for managing investor relations, including principles, responsibilities, communication methods, information disclosure, and compliance with relevant laws and stock exchange rules. The content is a governance and procedural manual rather than a financial report, earnings release, or announcement. It does not contain financial statements, audit opinions, voting results, or capital changes. It is a detailed governance-related document outlining internal rules and practices for investor relations management. Therefore, it fits best under Governance Information (CGR). The document length (8418 characters) and detailed procedural content support this classification with high confidence.
2022-04-12 Chinese
内幕信息知情人登记管理制度(2022年4月修订)
Governance Information Classification · 95% confidence The document is titled '内幕信息知情人登记管理制度' which translates to 'Insider Information Insider Registration Management System'. It is a detailed internal policy document outlining the management, registration, and confidentiality obligations of insiders who have access to material non-public information. It includes chapters on definitions, scope, confidentiality, registration procedures, insider trading restrictions, and responsibilities. The document references regulatory bodies such as the China Securities Regulatory Commission (中国证监会) and Shenzhen Stock Exchange (深交所), and discusses compliance with relevant laws and regulations. It is not a financial report, earnings release, or announcement of voting results. It is also not a report publication announcement or a certification. Instead, it is a governance-related document detailing internal rules and procedures for managing insider information and insider registration. Therefore, the most appropriate classification is Governance Information (CGR). The document length (over 10,000 characters) and detailed content confirm it is a substantive governance policy document, not a brief announcement or regulatory filing.
2022-04-12 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.